Skip Navigation

Skip Navigation

Issue No. 26  | June 24, 2011
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

Creative and Novel Ideas in HIV Research Grant Program Now Accepting Applications

“The International AIDS Society (IAS), in partnership with the U.S. National Institutes of Health (NIH) and the NIH-supported Centers for AIDS Research (CFAR) … announced the launch of a new round of the joint research grant programme, Creative and Novel Ideas in HIV Research (CNIHR).

“The CNIHR programme supports projects intended to advance the scientific understanding of HIV by exploring new approaches to pressing scientific questions on such issues as the long-term survival of individuals with HIV infection, strategies to control viral reservoirs and research leading toward a cure for HIV/AIDS, and new approaches for the prevention of HIV transmission including treatment as prevention. …

“Each awardee is funded for up to two years with up to $150,000 (direct costs) per year plus applicable indirect costs. …

“The first step of the competitive application process is now open on the CNIHR website ... and will close on 17 October 2011. Applicants will be asked to complete a two-step process to assess the quality of their research projects. Awardees will be selected by mid-April 2012 and will be able to start their research projects in June 2012. The research projects will be supported in collaboration with a CFAR institution with expertise in each candidate’s area of proposed research.”

More information is available:

  • International AIDS Society (IAS): Press release
  • Creative and Novel Ideas in HIV Research (CNIHR): Web site
  • Centers for AIDS Reseach (CFAR): Home page


Join AIDSinfo in Observing National HIV Testing Day

June 27, 2011, marks the 17th annual observance of National HIV Testing Day, a day that serves to promote the importance of HIV testing. The Centers for Disease Control and Prevention (CDC) reports that of the more than one million people in the United States living with HIV, one out of five do not know that they are infected. People who receive an early diagnosis are able to monitor their infection and begin treatment as soon as it is needed, which can lead to better control of the virus and may slow the progression to AIDS.

AIDSinfo has developed a specialty page for this awareness day with information and resources about HIV testing.

More information is available:


Study Examines Lipodystrophy in Treatment-Naive HIV-Infected People

“A5224s was a substudy of A5202, a trial of human immunodeficiency virus type 1 (HIV-1)-infected, treatment-naive subjects randomized to blinded abacavir-lamivudine (ABC-3TC) or tenofovir DF-emtricitabine (TDF-FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV-r). The primary endpoint was the presence of lipoatrophy (≥10% loss of limb fat) at week 96 by intent-to-treat (ITT) analysis. Secondary endpoints included changes in limb and visceral fat. … At week 96, estimated prevalence of lipoatrophy (upper 95% confidence interval [CI]) was 18% (25%) for ABC-3TC and 15% (22%) for TDF-FTC (P = .70); this was not significantly less than the hypothesized 15% for both (P ≥ .55 for both). The secondary as-treated (AT) analysis showed similar results. At week 96, the estimated mean percentage change from baseline in VAT [visceral adipose tissue] was higher for the ATV-r group than for the EFV group (26.6% vs 12.4%; P = .090 in ITT analysis and 30.0% vs 14.5%; P = .10 in AT analysis); however, the percentage change in VAT:TAT [total adipose tissue] was similar by ITT and AT analysis (P ≥ .60 for both). Results were similar for absolute changes in VAT and VAT:TAT. … ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT.”

More information is available:


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228